Read by QxMD icon Read

pneumococcal vaccine adverse effect

Meighan Palazzo, Gunjan L Shah, Olivia Copelan, Kenneth Seier, Sean M Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S Korde, Nikoletta Lendvai, Alexander M Lesokhin, Sham Mailankody, David J Chung, Guenther Koehne, C Ola Landgren, Heather Landau, Sergio A Giralt, Miguel-Angel Perales
Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Because of decreased vaccine rates among the general population causing loss of herd immunity, we aimed to establish the safety and efficacy of revaccinating multiple myeloma patients on lenalidomide maintenance (LM). Of the 122 patients who were vaccinated after aHCT between 2010 and 2014 at Memorial Sloan Kettering Cancer Center, 91 (75%) were on LM...
December 27, 2017: Biology of Blood and Marrow Transplantation
Huyen-Tran Nguyen, Phillip Minar, Kimberly Jackson, Patricia C Fulkerson
AIM: To determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population. METHODS: The electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers...
November 14, 2017: World Journal of Gastroenterology: WJG
David Goldblatt, Jo Southern, Nick J Andrews, Polly Burbidge, Jo Partington, Lucy Roalfe, Marta Valente Pinto, Vasilli Thalasselis, Emma Plested, Hayley Richardson, Matthew D Snape, Elizabeth Miller
BACKGROUND: Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in UK infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 schedule and to assess the potential effect on population protection. METHODS: In this multicentre, parallel group, randomised controlled trial, we recuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations by information booklets mailed out via the NHS Child Health Information Service and the UK National Health Application and Infrastructure Services...
February 2018: Lancet Infectious Diseases
Fatma Çiftci, Elif Şen, Nalan Demir, Orçun Çiftci, Serhat Erol, Oya Kayacan
OBJECTIVES: Vaccination of healthcare personnel (HCP) is an effective measure for preventing the spread of influenza among at-risk patients. This study was conducted to determine influenza vaccination rates and activities among HCP working at a tertiary healthcare setting. METHODS: This study included 470 HCP (85 physicians, 134 nurses, 53 healthcare assistants, 44 paramedics, 47 medical secretaries, and 107 auxillary staff members) working at the emergency, cardiology, chest diseases, and internal medicine departments with the largest volume of patients with vaccination indication of two large university hospitals with similar medical practices and work environment...
January 2, 2018: Human Vaccines & Immunotherapeutics
Angela E Rankine-Mullings, Shirley Owusu-Ofori
BACKGROUND: Persons with sickle cell disease (SCD) are particularly susceptible to infection. Infants and very young children are especially vulnerable. The 'Co-operative Study of Sickle Cell Disease' observed an incidence rate for pneumococcal septicaemia of 10 per 100 person years in children under the age of three years. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimens may be advisable for this population...
October 10, 2017: Cochrane Database of Systematic Reviews
Keiji Okinaka, Yukihiro Akeda, Saiko Kurosawa, Shigeo Fuji, Kinuko Tajima, Kazunori Oishi, Takahiro Fukuda
Few studies have evaluated the response of allogeneic hematopoietic stem cell transplantation [allo-HSCT] recipients to pneumococcal polysaccharide vaccine-23 [PPSV23] in the modern transplant era when more elderly patients undergo allo-HSCT. We administered a single dose of PPSV23 to 30 allo-HSCT recipients and evaluated serotype-specific antibody responses using IgG measured by enzyme-linked immunosorbent assay and opsonophagocytic assay [OPA] titers in a multiplexed opsonophagocytic killing assay. The median patient age was 54 years [range, 23-68], and the interval from allo-HSCT to vaccination was 756 days [range, 389-1903]...
September 29, 2017: Microbes and Infection
Samantha B Dolan, Manish Patel, Lee M Hampton, Eleanor Burnett, Daniel C Ehlman, Julie Garon, Emily Cloessner, Elizabeth Chmielewski, Terri B Hyde, Carsten Mantel, Aaron S Wallace
Background: In 2013, the World Health Organization's (WHO's) Strategic Advisory Group of Experts (SAGE) recommended that all 126 countries using only oral polio vaccine (OPV) introduce at least 1 dose of inactivated polio vaccine (IPV) into their routine immunization schedules by the end of 2015. In many countries, the addition of IPV would necessitate delivery of multiple injectable vaccines (hereafter, "multiple injections") during a single visit, with infants receiving IPV alongside pentavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haemophilus influenzae type b) and pneumococcal vaccine...
July 1, 2017: Journal of Infectious Diseases
Brenda Kwambana-Adams, Blake Hanson, Archibald Worwui, Schadrac Agbla, Ebenezer Foster-Nyarko, Fatima Ceesay, Chinelo Ebruke, Uzochukwu Egere, Yanjiao Zhou, Maze Ndukum, Erica Sodergren, Michael Barer, Richard Adegbola, George Weinstock, Martin Antonio
There is growing concern that interventions that alter microbial ecology can adversely affect health. We characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial component of the nasopharyngeal microbiome during infancy. Newborns were recruited into three groups as follows: Group1 (n = 33) was the control group and comprised infants who received PCV7 after 6 months and came from unvaccinated communities. Group 2 (n = 30) came from unvaccinated communities and Group 3 (n = 39) came from vaccinated communities...
August 15, 2017: Scientific Reports
Te-Yu Hung, Rishi S Kotecha, Christopher C Blyth, Sarah K Steed, Ruth B Thornton, Anne L Ryan, Catherine H Cole, Peter C Richmond
BACKGROUND: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13-valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding the benefit of PCV13 in immunocompromised children with cancer. METHODS: A prospective, open-label cohort study recruited children between ages 1 and 18 years who were receiving active immunosuppressive therapy (AIT) or were within 12 months after completing immunosuppressive therapy (CIT)...
November 1, 2017: Cancer
W Chatham, A Chadha, J Fettiplace, C Kleoudis, D Bass, D Roth, D Gordon
Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy...
December 2017: Lupus
Jeanet M Kemmeren, Nicoline At van der Maas, Hester E de Melker
In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) and universal hepatitis B vaccination has been introduced in the Netherlands. A questionnaire study was conducted to assess the tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked to report in questionnaires local reactions and systemic adverse events (AEs) before and after vaccination of their infant at 2, 3, 4, and 11 months of age...
June 2017: European Journal of Pediatrics
Alexandra Monastirli, Efstathia Pasmatzi, George Badavanis, Dionysios Tsambaos
Erythema multiforme (EM) is an acute and usually self-limited immune-mediated mucocutaneous disorder that is a hypersensitivity reaction to drugs, infections, and vaccines. Clinically, it is characterized by maculopapular, target-like lesions symmetrically distributed on the extremities (minor form) or additionally affecting one or more mucous membranes and causing epidermal detachment involving < 10% of the total body surface area (major form). We report a novel association between pneumococcal vaccination and the development of EM in a 2...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
M-S Agier, S Marchand, N Paret, S Gautier, A-P Jonville-Béra
OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13(®) since its commercialization. METHOD: Analysis of all adverse events reported with Prevenar 13(®) in France between 1st July 2010 and 31 October 2014. RESULTS: In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13(®) alone: 39 cutaneous AEs, 16 neurological AEs, four cases of collapse or shock, nine cases of fever, and one of thrombocytopenia...
May 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
Mtt Nguyen, H Lindegaard, O Hendricks, N Friis-Møller
OBJECTIVE: This study investigates predictors of influenza and pneumococcal vaccine coverage among rheumatoid arthritis (RA) patients, and explores possible differences according to type of RA therapy. METHOD: RA patients from two clinics in the region of Southern Denmark were informed about the survey during scheduled follow-up visits. The questionnaire included questions concerning previous influenza and pneumococcal vaccine uptake, attitudes about vaccination, and socio-demographic factors...
November 2017: Scandinavian Journal of Rheumatology
Sandra Sousa, Ana Catarina Duarte, Inês Cordeiro, Joana Ferreira, Maria João Gonçalves, Tiago Meirinhos, Teresa Martins Rocha, Vasco C Romão, Maria José Santos
INTRODUCTION: Children and adolescents with systemic rheumatic diseases have an increased risk of infections. Although some infections are vaccine-preventable, immunization among patients with juvenile rheumatic diseases is suboptimal, partly due to some doubts that still persist regarding its efficacy and safety in this patient population. OBJECTIVES: To review the available evidence regarding the immunological response and the safety of vaccination in children and adolescents with systemic inflammatory rheumatic diseases (SIRD)...
January 2017: Acta Reumatológica Portuguesa
T Azegami, Y Yuki, S Sawada, M Mejima, K Ishige, K Akiyoshi, H Itoh, H Kiyono
Obesity is associated with multiple comorbidities such as cardiovascular diseases and has a huge economic impact on the health-care system. However, the treatment of obesity remains insufficient in terms of efficacy, tolerability, and safety. Here we created a nasal vaccine against obesity for the first time. To avoid the injectable administration-caused pain and skin-related adverse event, we focused on the intranasal route of antigen delivery. We developed a vaccine antigen (ghrelin-PspA (pneumococcal surface protein A)), which is a recombinant fusion protein incorporating ghrelin, a hormone that stimulates food intake and decreases energy expenditure, and PspA, a candidate of pneumococcal vaccine as a carrier protein...
September 2017: Mucosal Immunology
Julia Ae Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood-Baker
BACKGROUND: People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs. OBJECTIVES: To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. SEARCH METHODS: We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms...
January 24, 2017: Cochrane Database of Systematic Reviews
Cornelius Remschmidt, Thomas Harder, Ole Wichmann, Christian Bogdan, Gerhard Falkenhorst
BACKGROUND: In many industrialized countries routine vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) is recommended to prevent pneumococcal disease in the elderly. However, vaccine-induced immunity wanes after a few years, and there are controversies around revaccination with PPSV-23. Here, we systematically assessed the effectiveness and safety of PPSV-23 revaccination. METHOD: We conducted a systematic literature review in MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials from inception to June 2015...
November 25, 2016: BMC Infectious Diseases
Mark Doherty, Ruprecht Schmidt-Ott, Jose Ignacio Santos, Lawrence R Stanberry, Annika M Hofstetter, Susan L Rosenthal, Anthony L Cunningham
One of the strategic objectives of the 2011-2020 Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people. This approach encompasses special groups at increased risk of vaccine-preventable diseases, such as preterm infants and pregnant women, as well as those with chronic and immune-compromising medical conditions or at increased risk of disease due to immunosenescence. Despite demonstrations of effectiveness and safety, vaccine uptake in these special groups is frequently lower than expected, even in developed countries with vaccination strategies in place...
December 20, 2016: Vaccine
M Tashani, M Alfelali, O Barasheed, A S Alqahtani, L Heron, M Wong, H Rashid, R Booy
Sequential or co-administration of vaccines has potential to alter the immune response to any of the antigens. Existing literature suggests that prior immunisation of tetanus/diphtheria-containing vaccines can either enhance or suppress immune response to conjugate pneumococcal or meningococcal vaccines. We examined this interaction among adult Australian travellers before attending the Hajj pilgrimage 2014. We also investigated tolerability of these vaccines separately and concomitantly. We randomly assigned each participant to one of three vaccination schedules...
November 21, 2016: Vaccine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"